Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
oral GLP-1
Advertisement
Structure Therapeutics Reports Positive Oral Weight-Loss Data
SAN FRANCISCO — September 8, 2026 Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs...
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Novo Nordisk Secures EU Approval for Oral Wegovy
BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...
Advertisements
Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Ambrosia’s AMB-702 Shows Superior Weight Loss in Preclinical GLP-1 Studies
BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Rivus Highlights RV-8451 Muscle-Preserving Obesity Data
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...
Advertisement
